Navigation Links
Biotec Pharmacon Announces Preliminary Results from the,Sloan-Kettering Clinical Study

TROMSØ, Norway, June 29, 2007-Preliminary results from the immunotherapeutic cancer study at Memorial Sloan-Kettering Cancer Center show a very good safety profile for SBG. Furthermore, encouraging responses on cancer development have been observed among several patients that have been treated with SBG in combination with the monoclonal antibody against neuroblastoma.

In line with the timetable described in the company's report for the 1st quarter 2007, all 24 patients have now been included in the clinical study at Memorial Sloan-Kettering Cancer Center (MSKCC). In this study, SBG is tested in combination with a monoclonal antibody (3F8) against the cancer form neuroblastoma. The patients are children that have developed metastatic neuroblastoma and are non-responders to previous conventional chemotherapy. These patients therefore maintain a very poor prognosis for survival, but earlier clinical studies at Sloan-Kettering have demonstrated positive effects in a similar patient population when treated with the cancer antibody 3F8. By using immune-stimulating adjuvants such as beta-glucans, the effects of the antibody treatment could be improved. The purpose of the present study was primarily to investigate if SBG leads to side effects in this particular combination treatment, but also to obtain the first indications whether SBG has a role together with monoclonal antibodies in the treatment of cancer patients.

Patients in the study have been treated at escalating dose levels of SBG from 10 and up to 120 milligram per kilo per day at the highest level. Of 24 patients that have been included in the trial, 23 patients are evaluable for safety, whereas 20 patients are evaluable for response. Sloan-Kettering has now reported preliminary data for these patients. It should be noted that the results are not considered definitive.

With a possible exception of one single incident, there are no
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
6. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
7. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
8. Prana Biotechnology Presents New Key Findings on PBT2
9. Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
10. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
Post Your Comments:
(Date:9/4/2008)...X-351 awarded orphan designation for the treatment...eukemia, PRINCETON, N.J., Sept. 4 /-...U.S. Food & Drug Administration (FDA) has granted ...norubicin) Liposome Injection,for the treatment of...tly preparing to conduct two randomized Phase 2,st...
(Date:9/4/2008)...her Roche first in TaqMan(R) real-time PCR testing... lab, PLEASANTON, Calif., Sept. 4 /PRNewswire/ ...pproved the Roche COBAS(R) TaqMan(R) HBV Test,the...A approved in the U.S.,The test uses Roche,s real-...titis B virus DNA in a patient,s blood. Doctors ma...
(Date:9/4/2008)...ractice Bulletin for Obstetrician-Gynecologists St...ice Change-Minimally Invasive Interventional,Radio... With Uterine,Fibroids, FAIRFAX, Va., Sept. 4 /PR...nal Radiology, a national organization of nearly 4...ionals dedicated to improving health,care through ...
(Date:9/4/2008)...tal Study Seeks to Enroll 750 Women at More Than 1...- QuatRx Pharmaceuticals, a,privately...ment and,commercialization of compounds to treat e...today announced that it has initiated a second,Pha...ets), the company,s,estrogen-free oral therapy in ...
Breaking Medicine Technology:Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 2Society of Interventional Radiology Applauds Report's Uterine Fibroid Embolization Recommendations 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 1NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 2NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 3NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration 1620 4Steroids Seem Safe for Babies at Risk of Early Birth 1618 1Steroids Seem Safe for Babies at Risk of Early Birth 1618 2Steroids Seem Safe for Babies at Risk of Early Birth 1618 3Pennsylvania Needs More Lung Cancer Research 1615 1STAAR Surgical Reports Operational Progress 1612 1STAAR Surgical Reports Operational Progress 1612 2STAAR Surgical Reports Operational Progress 1612 3STAAR Surgical Reports Operational Progress 1612 4
...IRE)--Apr 30, 2007 - CollaGenex,Pharmaceuticals, I...t in the May 2007 issue of the Journal of the Amer...zed phase III clinical trials,demonstrated the ef...cline (Oracea(R), 40-mg doxycycline, USP capsules)...cluded these studies,establish the first important...
...IRE)--Apr 30, 2007 - Hemispherx Biopharma,Inc. (A...lication,(Journal of Immunology, April 2007) that ...proprietary experimental therapeutic,Ampligen(R) ...g,tested as a monotherapy for Chronic Fatigue Synd...s., The new peer-reviewed study shows conclusively...
Other Medicine Technology:Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 2Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 3Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory,Dose Doxycycline for the Treatment of Rosacea 4New Report Illuminates Ampligen's Unique Mechanism of Action 2New Report Illuminates Ampligen's Unique Mechanism of Action 3New Report Illuminates Ampligen's Unique Mechanism of Action 4
(Date:9/4/2008).... Free drug samples provided to physicians by pha...insured patients more in the long run, according t...rsity Baptist Medical Center and colleagues. , T...abits of more than 70 physicians in a university-a... immediately before and after the closing of their...
(Date:9/4/2008)...n a case-control study, the presence of measles vi... and GI disturbances than in children with only GI... onset were unrelated to MMR vaccine timing. Stud...ary of Science on September 4 ( http://dx.plos.or... implementation of measles vaccines in 1963, three...
(Date:9/4/2008)...ence of instructions they say could help doctors e...lthDay News) -- Vaccine safety experts say that al...eive vaccinations with close monitoring and a set ...ptember issue of Pediatrics , a team of experts l...h a step-by-step set of instructions -- an algorit...
(Date:9/4/2008)...ger labeling about fungal infection risk , ...l health authorities have asked the manufacturers ...ster safety warnings on the risk of developing opp...ra, Cimzia, Enbrel and Remicade, belong to a class...ha blockers (TNF-alpha blockers), which suppress t...
Breaking Medicine News(10 mins):Health News:Free drug samples may end up costing uninsured more 2Health News:Free drug samples may end up costing uninsured more 3Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 2Health News:Study firmly shows no connection between measles, mumps, rubella (MMR) vaccine and autism 3Health News:Even Kids With Known Allergies Can Be Safely Vaccinated 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...olocaust are more likely to suffer from cancer and...d his colleagues at Israel's //Haifa University su...ear-starvation of European Jews during World War I...at the incidence and death rate from cancer in aro...
... of Goan’s can be the main cause for HIV/AIDS spre...ollow the Government policies // and initiatives t...Many labourers who got jobs in Goa, since it has b...ing with them the dreadful virus (HIV) when they a...
...er gave Isabelle Taylor, of St Annes, Lancs, a mob... grand child would end up constantly // sending te...loping a condition known as ‘repetitive strain in...n in Britain to suffer from this condition. Her m...
... researchers plan to ask women to donate their egg... cells matched to patients // which they say would...ng diseases such as diabates or neurodegenerative ...nic stem (ES) cells after creating human embryos c...
Other Medicine News:
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing.
Medicine Products: